Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Techno Network Shikoku Co., Ltd.

Tecno Network Shikoku Co., Ltd.

Jnc Corporation

Kyowa Kirin Co., Ltd.

Toshiyuki Suzawa

Motoo Yamasaki

Kenji Shibata

Takeo Tanaka

Ken Kobayashi

Eiji Tsukuda

Tatsuhiro Ogawa

Kumiko Maruyama

Keiichi Yano

Kazuo Yamaguchi

Isao Kawamoto

Yuzuru Matsuda

Shigeto Kitamura

Shigeru Chiba

Mayumi Yoshida

Yoshikazu Morishita

Chieko Bando

Mika Makino

Toshihide Ikemura

Nobuo Hanai

Tatsuya Murakami

Shiro Akinaga

Hiromitsu Saito

Masami Okabe

Satoru Nagamura

So Ohta

Hisao Nemoto

Takashi Kuwabara

Kinya Yamashita

Mayumi Mukai

Tsutomu Sugihara

Hiroyuki Yamaguchi

Koji Yamada

Tetsuji Ohno

Shigeyuki Aoyama

Noboru Konishi

Yasuki Kato

Shiro Soga

Hiroko Kusano

Masahiro Yamauchi

Noriko Sakurai

Tomonari Urakubo

Tomoko Isoda

Yuya Taniguchi

Hidetaka Nomura

Setsuko Onodera

Noriko Sukurai

Takashi Ishihara

Yasuaki Suzuki

Yoshihiro Matsumoto

The present invention relates to protein purification. More particularly, a method for directly recovering an objective protein from a protein composition and purifying a protein with a desired quality in a rapid and efficient manner is provided. Further, a rapid purification method capable of efficiently removing impurities included in the protein composition is provided. Therefore, compared to the conventional purification methods, quality and yield of the protein can be remarkably improved.

Method for purifying protein

The provision of an antithrombin composition having a desired &#x3b1;-form content rate or &#x3b2;-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired &#x3b1;-form content rate or &#x3b2;-form content rate which is prepared by contacting an antithrombin-containing aqueous solution with a Cellufine Sulfate chromatography carrier.

Method for producing antithrombin composition

Objects of the present invention are to provide a compound which is useful as a surface modifier for producing a drug carrier or the like, or a salt thereof; a fine particle comprising the same; and the like. The present invention provides a compound in which a substance to be modified, which is selected from the group consisting of an amphiphilic substance and a hydrophobic substance, is modified with a glycerol derivative represented by the following formula (1): wherein R represents a residue comprising a reactive group for the substance to be modified, which is selected from the group consisting of an amphiphilic substance and a hydrophobic substance or for a spacer capable of binding the substance to be modified, which is selected from the group consisting of an amphiphilic substance and a hydrophobic substance, to R-X, or a group capable of being transformed into the reactive group; n represents an integer of 3 or more; and X represents a residue capable of having the following structure by n in number: directly or via the spacer, or a salt thereof; a fine particle comprising the same; and the like.

Compound modified with glycerol derivative

The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.

Platelet production promoting agent

(wherein R represents a residue comprising a reactive group or a group capable of being transformed into the reactive group; n represents an integer of 3 or more; and X represents a residue capable of having the following structure by n in number: Rs each represent a hydrogen atom or a group capable of being transformed into a hydrogen atom, and 6 or more of Rs may be the same or different) The compound represented by the above formula (1), which is capable of modifying a physiologically active polypeptide or a derivative thereof, or a low molecular compound while maintaining the physiological activity, or which is useful for improving the stability or water-solubility of the low molecular compound, are provided.

Glycerol derivative

The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

Branched polyalkylene glycols

The present invention relates to a chemically modified polypeptide in which at least one of hydroxyl groups in the polypeptide molecule is modified with a polyalkylene glycol derivative; a method for producing the modified polypeptide; a method of treatment using the modified polypeptide; use of the modified polypeptide; a pharmaceutical preparation comprising the modified polypeptide; and a composition for treatment comprising the modified polypeptide.

Chemically modified polypeptides

The present invention provides peptides represented by the following formula (A):wherein Q represents a physiologically active peptide moiety; X each represents the same or different &#x3b1;-amino acid residue; M represents Gly or Cys; m represents an integer of from 5 to 8; and n represents an integer of from 0 to 3, or their pharmaceutically acceptable salts thereof. The peptides of the present invention have higher stability and/or higher activity than physiologically active linear peptides to which no cyclic peptide is bonded.

Peptides

Endothelin-antagonizing peptide

The present invention relates to a toxin conjugate in which a residue derived from a compound having an affinity for a target cell is bound to a toxin through a spacer comprising polyalkylene glycol and dipeptide.

Toxin conjugates

The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Strains of streptomyces producing endothelin antagonistic peptides

Growing community of inventors

Tokyo, Japan

Toshiyuki Suzawa